2019 AACR-NCI-EORTC (ANE) Molecular Targets: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample

While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomic profiling. This is critical for identifying new biomarker signatures that can effectively stratify responders and non-responders, in addition to understanding mechanisms of tumor resistance and guiding the rational design of personalized cancer therapeutics. Traditionally, generating information relating to multiple, potential biomarkers of interest has necessitated the use of several assay technologies from various sources. This is not only impractical given the often limited quantity of precious patient samples, but it also introduces complexities associated with the integration and interpretation of disparate reporting formats and is prohibitively costly.

Here, we present our solution to these issues, the ImmunoID NeXT Platform™. ImmunoID NeXT is a universal cancer immunogenomics platform that consolidates multiple biomarker assays into one; providing a multidimensional view of the tumor and its TME from a single sample. It combines the pioneering NeXT assay (exome and transcriptome), sophisticated analytics engines, and quality support to provide researchers with the comprehensive immunogenomic data they need to drive their drug development programs.